Job as Medical Repersentative in A leading Pharmacy company with oncology & Critical Care Division- Proficio
A leading Pharmacy company with oncology & Critical Care Division
Post: Medical Repersentative
[adsense:336x280:8701650588]
Researchers have identified a class of compounds that could help combat a virus which has stricken children with serious respiratory infections and is also associated with polio-like symptoms.
Novartis announced results from the pivotal Phase III clinical trial demonstrating Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with polycythemia vera (PV) who had an inadequate response to or unacceptable side effects from hydroxyurea as defined according to the modified European LeukemiaNet (ELN) criteria, which is published in The New England Journal of Medicine (NEJM). In PV, hematocrit control and spleen size reduction are key measures of a patient's response to therapy.
Scientists have discovered the unconventional way the cholera bacterium stabs and kills other bacteria to steal their DNA, making it potentially more virulent. Cholera is caused when the bacterium Vibrio cholerae (V cholerae) infects the small intestine. The disease is characterised by acute watery diarrhea resulting in severe dehydration.